A second chance at prevention: could provider training shield cancer survivors from HPV-Related cancers?
NCT ID NCT04469569
First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time
Summary
This trial tests whether a program that trains pediatric oncology providers—called HPV-PROTECT—can increase HPV vaccination among young cancer survivors aged 9 to 17 who are at least one year past treatment. These survivors face a higher risk of new cancers caused by HPV, yet vaccination rates are low. The program includes communication training, peer feedback, and a toolkit to help providers make strong vaccine recommendations. The study will compare clinics using the program to those providing usual care, measuring how many survivors start the HPV vaccine series.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- HPV-PROTECT, a provider-focused behavioral intervention including communication training, peer feedback, and a toolkit
- What this could lead to
- If effective, this approach could increase HPV vaccination among young cancer survivors, potentially preventing HPV-related cancers in this high-risk group.
- What could go wrong
- The trial's success depends on provider behavior change and may not generalize beyond participating clinics. Vaccine uptake could remain low due to other barriers.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
8,120 people
The number who actually took part.
- Started
-
Feb 2021
- Finished
-
Dec 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
9 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. HEALTHCARE PROVIDERS (ONCOLOGISTS, ADVANCED PRACTICE PROVIDERS) * ≥18y of age * Care for cancer survivors seen in the targeted clinic who are age 9-17y, ≥1y off-therapy, and reside in the state where clinic is located * Licensed to order vaccines * Willing to complete surveys and/or interviews 2. CHILDHOOD CANCER SURVIVORS * 9-17y of age * ≥1y following completion of cancer therapy * Reside in the state where clinic is located * Receive follow-up care (in person or via telehealth) at the participating sites Exclusion Criteria: N/A
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Papillomavirus vaccines are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Baylor College of Medicine
Houston, Texas, 77030-3411, United States
-
Emory University
Atlanta, Georgia, 30322, United States
-
Oregon Health and Science University
Portland, Oregon, 97239-3098, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35233, United States
-
University of Minnesota
Minneapolis, Minnesota, 55455-0341, United States
-
Wake Forest University Health Sciences
Winston-Salem, North Carolina, 27157-0001, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.